Comparison of the effects of intravenous and oral montelukast on airway function: A double blind, placebo controlled, three period, crossover study in asthmatic patients

Thorax

Volumn 55, Issue 4, 2000, Pages 260-265

  Dockhorn, R J ^c   Baumgartner, R A ^b   Leff, J A ^b   Noonan, M ^d   Vandormael, K ^a   Stricker, W ^e   Weinland, D E ^b   Reiss, T F ^b  

^a MSD   (Belgium)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Intl Med Tech Consultants Inc   (United States)

^d Allergy Associates Research Center   (United States)

^e Clinical Research of the Ozarks   (United States)

Author keywords

Asthma; Leukotriene receptor antagonist; Montelukast

Indexed keywords

ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; MONTELUKAST; NEDOCROMIL; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS;

ACETATES; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTI-ASTHMATIC AGENTS; ASTHMA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; QUINOLINES;

EID: 0034057041     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.55.4.260     Document Type: Article

References (30)

1. 1 Woolcock AJ, Peat JK. Evidence for the increase in asthma worldwide. In: The rising trends in asthma. Ciba Foundation Symposium 206. Chichester: John Wiley and Sons, 1997:122-39.
2. 2 Kardon EM. Acute asthma. Emerg Med Clin North Am 1996;14:93-114.
3. 3 Lipworth BJ. Treatment of acute asthma. Lancet 1997;350(Suppl II):18-23.
4. 4 Drazen JM, O'Brien J, Sparrow D, et al. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992;146:104-8.
5. 5 Samuelsson B. Leukotrienes: mediators of immediate hypcrsensitivity reactions and inflammation. Science 1983;220:568-75.
6. 6 Drazen JM, Austen FK, Lewis RA, et al. Comparative airway and vascular activity of leukotriene C-1 and D in vivo and in vitro. Proc Natl Acad Sci USA 1980;77:4345-58.
7. 7 Marom ZVI, Shelhamer JH, Bach MK, et al. Slow-reacting substances, leukotriene C4 and D4 increase the release of mucus from human airways. Am Rev Respir Dis 1982;126:449-51.
8. 8 Barnes NC, Piper PJ, Costello JF. Comparative actions of inhaled leukotriene C4, leukotriene D4 and histamine in normal subjects. Thorax 1984;39:500-4.
9. 9 Knorr B, Matz J, Bernstein JA, et al, Montelukast for chronic asthma in 6 to 14-year-old children: a randomized, double-blind trial. JAMA 1998;279:1181-6.
10. 10 Reiss TF, Chervinsky P, Dockhorn RJ, et al. Montelukast, a once daily leukotriene receptor antagonist, in the treatment of chronic asthma. A multicenter, randomized, double-blind trial. Arch Intern Med 1998;158:1213-20.
11. 11 American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995;152:1107-36.
12. 12 Cheng H, Leff JA, Amin R, et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res 1996;13:445-8.
13. 13 Altman LC, Munk Z, Seltzer J, et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. J Allergy Clin Immunol 1998;102:50-6.
14. 14 Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur Respir J 1998;11:1232-9.
15. 15 Bronsky EA, Kemp JP, Zhang J, et al. Dose-related protection of exercise bronchoconstrition by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther 1997;62:556-61.
16. 16 Reiss TF, Sorkness CA, Stricker W, et al. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997;52:45-8.
17. 17 Impens N, Reiss TF, Teahan JA, et al. Acute bronchodilation with an intravenously administered leukotriene D4 antagonist, MK-679. Am Rev Respir Dis 1993;147:1442-6.
18. 4-receptor antagonist. N Engl J Med 1990;323:1736-9.
19. 4) receptor antagonist (MK-0571) in patients with asthma. Am Rev Respir Dis 1992;146:358-63.
20. 20 Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991;337:1062-3.
21. 21 Reiss TF, Sorkness CA, Stricker W, et al. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997;52:45-8.
22. 22 McDermott MF, Murphy DG, Zalenski RJ, et al. A comparison between emergency diagnostic and treatment unit and inpatient care in the management of acute asthma. Arch Intern Med 1997;157:2055-62.
23. 23 US Public Health Service. Healthy People 2000: National Promotion and Disease Prevention Objectives - Full Report. Washington, DC: US Dept of Health and Human Services PHS 91-50212, 1990: 1-692.
24. 24 Strauss L, Hejal R, Galan G, et al. Observations on the effects of aerosolized albuterol in acute asthma. Am J Respir Crit Care Med 1997;155:454-8.
25. 25 FitzGerald JM, Grunfeld A, Pare PD, et al. The clinical efficacy of combination nebulized anticholinergic and adrenergic bronchodilators vs nebulized adrenergic bronchodilator alone in acute asthma. Canadian Combivent Study Group. Chest 1997;111:311-5.
26. 26 McFadden ER, El Sandadi N, Strauss L, et al. The influence of parasympatholytics on the resolution of acute attacks of asthma. Am J Med 1997;102:7-13.
27. 27 Fanta CH, Rossing TH, McFadden ER. Emergency room treatment of asthma. Am J Med 1982;72:416-22.
28. 28 Rossing TH, Fanta CH, McFadden ER, et al. A controlled trial of the use of single vs combined-drug therapy in the treatment of acute episodes of asthma. Am Rev Respir Dis 1981;123:190-4.
29. 29 Tan KS, Grove A, McLean A, et al. Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 1997;156:28-35.
30. 30 Lin RY, Pesola GR, Westfal RE, et al. Early parenteral corticosteroid administration in acute asthma. Am J Emerg Med 1997;15:621-5.